First Eagle Investment Management LLC lowered its stake in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 38.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 5,190,398 shares of the company's stock after selling 3,259,314 shares during the quarter. First Eagle Investment Management LLC owned 0.12% of Haleon worth $46,714,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in HLN. Bessemer Group Inc. increased its stake in shares of Haleon by 4.8% in the third quarter. Bessemer Group Inc. now owns 25,659 shares of the company's stock worth $232,000 after buying an additional 1,185 shares during the period. Hantz Financial Services Inc. boosted its position in Haleon by 2.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 873,211 shares of the company's stock valued at $7,859,000 after buying an additional 21,027 shares during the period. Trillium Asset Management LLC boosted its position in Haleon by 44.0% during the 3rd quarter. Trillium Asset Management LLC now owns 353,378 shares of the company's stock valued at $3,180,000 after buying an additional 107,951 shares during the period. Fisher Asset Management LLC boosted its position in Haleon by 2.4% during the 3rd quarter. Fisher Asset Management LLC now owns 337,691 shares of the company's stock valued at $3,039,000 after buying an additional 7,800 shares during the period. Finally, Altar Rock LLC grew its holdings in Haleon by 12.3% in the 3rd quarter. Altar Rock LLC now owns 15,914 shares of the company's stock worth $148,000 after acquiring an additional 1,739 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on HLN shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Haleon in a research note on Friday, September 25th. Zacks Research cut Haleon from a "hold" rating to a "strong sell" rating in a research note on Thursday, October 22nd. Deutsche Bank upgraded Haleon from a "sell" rating to a "hold" rating in a report on Friday, October 30th. Royal Bank Of Canada reaffirmed a "sector perform" rating on shares of Haleon in a research report on Tuesday, August 11th. Finally, Berenberg Bank reaffirmed a "buy" rating on shares of Haleon in a research report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $4.90.
Read Our Latest Report on Haleon
Haleon Stock Performance
Shares of HLN opened at $9.06 on Wednesday. The company has a 50-day simple moving average of $9.33 and a two-hundred day simple moving average of $9.71. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.69 and a quick ratio of 0.52. The firm has a market capitalization of $39.81 billion, a PE ratio of 23.22, a price-to-earnings-growth ratio of 2.16 and a beta of 0.15. Haleon PLC Sponsored ADR has a one year low of $8.38 and a one year high of $11.28.
Haleon Profile
(
Free Report)
Haleon plc is a global consumer healthcare company that develops and sells nonprescription health products. Its portfolio spans oral health, pain relief, vitamins and supplements, respiratory health, digestive health, and therapeutic skin care. Its brands include Sensodyne, parodontax and Polident in oral care; Advil, Panadol and Voltaren for pain relief; and Centrum, Emergen-C and Theraflu in supplements and respiratory care. Haleon sells its products in markets around the world. Haleon became an independent public company in 2022 after separating from GSK.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.